NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing...
NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing...
neurobo pharmaceuticals 在肥胖治疗DA-1726的一期试验MAD第二部分中给第一名患者注射剂量;第一部分的最终数据预计于2024年第3季度公布,第二部分预计于2025年第1季度公布;计划的第三部分将评估24周的体重减轻情况;$70M融资将用于持续进行...